Today's Edition
ABU DHABI (WAM)
Abu Dhabi Stem Cells Centre (ADSCC) and Burjeel Holdings PLC have announced a strategic partnership to expand bone marrow transplant and cellular therapy in the Group’s flagship facility, Burjeel Medical City (BMC).
This collaboration aims to enhance access to advanced care for adult and paediatric patients with blood cancer, genetic diseases, autoimmune diseases, and others. The strategic move will pave the way for an extensive, integrated ecosystem for advanced research and cellular therapy, and further reinforce Abu Dhabi’s status as a global healthcare destination.
Under the agreement, ADSCC will work together with Burjeel Medical City to increase accessibility for patients in the UAE and across the region.
AD-BMT expertise and the shared vision of both institutions align with Abu Dhabi’s mission to establish itself as a global centre of medical excellence and innovation. Both new and existing BMC and ADSCC patients will benefit from this partnership.
The partnership also focuses on leveraging regenerative medicine services. ADSCC is at the forefront of offering cutting-edge treatments for orthopedic, neurological, rheumatological, autoimmune, and burn-related conditions through the use of stem cells and advanced cellular therapies. BMC will integrate these innovative services into their various specialties to enhance patient care.
John Sunil, Chief Executive Officer of Burjeel Holdings, said, “Our vision is to create a comprehensive, world-class bone marrow transplant programme that delivers the highest standards of care while also pushing the boundaries of innovation. This partnership is a major step forward in achieving that goal. Together, we are setting new benchmarks in patient outcomes and medical excellence.”
Prof. Yendry Ventura, Chief Executive Officer of ADSCC and Adjunct Professor at UAE University, commented, “Guided by the UAE's visionary leadership, ADSCC was the first to introduce bone marrow transplantation and cellular therapy in the UAE in 2020, providing advanced critical care regionally and running high-level research and clinical trials in the field. As demand grew, ADSCC expanded to offer CAR-T Cell Therapy, offering further cutting-edge treatment options to patients.”
Dr. Fatima Alkaabi, Executive Director of Abu Dhabi Bone Marrow Transplant Programme at ADSCC, said, “This collaboration marks a transformative moment for expanding bone marrow transplant in UAE. By extending the advanced research and clinical capabilities of ADSCC with BMC’s robust infrastructure and expertise, we are not only enhancing the standards of care for our patients but also reinforcing Abu Dhabi’s position as a life sciences hub.”
Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, stated, “This partnership represents a crucial advancement in our ability to provide comprehensive and cutting-edge care to patients with complex haematological conditions. By combining the expertise of both institutions, we are creating a seamless continuum of care and driving forward the research and clinical practices that will shape the future of regenerative medicine and haematology in the region.”
